Professor Richard Price
Curing Plasmodium vivax malaria
Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.
Professor of Tropical Medicine
The main focus of our translational research programme is to improve the diagnosis and management of vivax malaria. To achieve this we are working with in malaria endemic countries across the Asia-Pacific region and Horn of Africa to:
- optimise the safe and effective radical cure of vivax malaria,
- improve the molecular surveillance of drug resistant malaria
- define the morbidity and mortality of vivax malaria
- evaluate the impact and cost effectiveness of novel treatment and malaria control activities.
The programme is being conducted in collaboration with the Mahidol Oxford Research Unit (MORU) in Thailand and the Menzies School of Health Research (MSHR) in Darwin.
I am head of the clinical module of the World Wide Antimalarial Resistance Network (WWARN). Between 2010-2020 he established co-chair the Vivax Working Group of the Asia-Pacific Malaria Elimination Network (APMEN).
- Clinical trials and implementation studies of different primaquine regimens
- Field testing novel G6PD diagnostics
- Mapping populations at risk of malaria and drug induced haemolysis
- Determining the molecular basis of chloroquine resistant P. vivax
- Individual patient data metanalyses of antimalarial efficacy studies
Timika, Papua, Indonesia
Sumatra Site for IMPROV Study
Ex vivo Lab
Walker CR. et al, (2023), Epidemics, 100687 - 100687
Rahmalia A. et al, (2023), Malaria journal, 22
Sadhewa A. et al, (2023), Pathogens, 12, 650 - 650
Penjor K. et al, (2023), Journal of Travel Medicine
Siegel SV. et al, (2023), medRxiv
Yilma D. et al, (2023)